In the present study, we aim to explore the molecular landscape of ERBB2 alterations in solid tumors by next-generation sequencing (NGS), which will provide additional evidence for the panorama of these therapeutic targets in the Chinese cancer population. Here, ERBB2 is linked to cancer.